ArticleJournal of nanobiotechnology2025
Bioinspired catalytic nanogel as an inflammatory cascade-targeted therapeutic for rheumatoid arthritis.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Cell death crosstalk in NET-Driven inflammation: mechanisms, disease contexts, and therapeutic perspectives.Biomarker research · 2026Review
- Exploring the Potential of Transdermal Nanobilosomal Gel for Magnified Anti-Inflammatory Efficacy of Thymol for Managing Rheumatoid Arthritis.Gels (Basel, Switzerland) · 2026Article
- Nanozyme-Mediated Joint Homeostasis Restoration: Emerging Strategies for Arthritis Therapy.International journal of nanomedicine · 2026Review
- Nanozymes for Bone Regeneration: Mechanistic Insights into Immune and Metabolic Microenvironment Modulation.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The inflammatory cascade is a key driver of chronic inflammation in rheumatoid arthritis (RA) and facilitates the migration of circulating immune cells into the inflamed joints. Recent studies have unveiled the complexity of this cascade, which involves intricate interactions between immune cells, neutrophil extracellular traps (NETs), reactive oxygen species (ROS), and inflammatory cytokines. Given the central role of the inflammatory cascade in RA pathogenesis, targeting it represents a highly promising therapeutic strategy. However, research specifically focused on modulating the inflammatory cascade remains limited. In this study, we introduce a novel bioinspired catalytic nanogel designed to target the inflammatory cascade for the immunotherapy of RA. Nanogel coated with cationic polymer enables the targeted penetration into cartilage as well as the capture of NETs via charge-trapping effects. The captured NETs are further degraded by DNase I-conjugating nanogel. To fundamentally reduce ROS that can induce NETs generation, nanogels exhibit intrinsic catalase, superoxide dismutase, and hydroxyl radical activities, effectively inhibiting oxidative stress responses. Of note, the enhanced therapeutic effects are observed in mouse RA model including targeted and long-term accumulation of cascade nanogel in the inflamed joints, efficient NETs scavenging, alleviated intra-articular inflammation, and reduced bone destruction. Also, transcriptome analysis indicates that nanogel treatment markedly downregulates NETs formation signaling pathway, upregulates anti-inflammatory pathways and finally reduces neutrophil infiltration-caused autoimmune damage. These results make the bioinspired catalytic nanogel system an ideal inflammatory cascades-targeting therapy for the systemic autoimmune disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.